Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Lucas Swanson"'
Autor:
Meredith Li, Faeze Keshavarz-Rahaghi, Gale Ladua, Lucas Swanson, Caroline Speers, Daniel J. Renouf, Howard J. Lim, Janine M. Davies, Sharlene Gill, Heather C. Stuart, Stephen Yip, Jonathan M. Loree
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Introduction: In metastatic colorectal cancer (mCRC), RAS mutations impart inferior survival and resistance to anti-epidermal growth factor receptor (EGFR) antibodies. KRAS G12C inhibitors have been developed and we evaluated how KRAS G12C differs fr
Externí odkaz:
https://doaj.org/article/70b93efc525b4e4daeb4ed9d88c396ef
Autor:
Jonathan M. Loree, David F. Schaeffer, Scott Kopetz, Aly Karsan, Robert Wolber, Sharlene Gill, Daniel J. Renouf, Howard J. Lim, Lucas Swanson, Kanwal Raghav, Van K. Morris, Laveniya Kugathasan, Benny Johnson, Jenny E. Chu
Kaplan-Meier estimation of (A) overall survival of BRAFV600E mCRC NGS cohorts and (B) progression free survival of BRAFV600E mCRC NGS cohorts from BC Cancer and MD Anderson shows no difference in overall or progression free survival.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84cbb28eff52886ab454880c44d38469
https://doi.org/10.1158/1078-0432.22476714
https://doi.org/10.1158/1078-0432.22476714
Autor:
Jonathan M. Loree, David F. Schaeffer, Scott Kopetz, Aly Karsan, Robert Wolber, Sharlene Gill, Daniel J. Renouf, Howard J. Lim, Lucas Swanson, Kanwal Raghav, Van K. Morris, Laveniya Kugathasan, Benny Johnson, Jenny E. Chu
Prevalence of BRAFV600E mutated colorectal cancer by IHC testing within VCH population-based cohort.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bdb7991ab888c2ec8c2b57983e5f0a5
https://doi.org/10.1158/1078-0432.22476705.v1
https://doi.org/10.1158/1078-0432.22476705.v1
Autor:
Benny Johnson, David F. Schaeffer, Laveniya Kugathasan, Kanwal Pratap Singh Raghav, Daniel J. Renouf, Jenny E. Chu, Scott Kopetz, Aly Karsan, Lucas Swanson, Sharlene Gill, Howard John Lim, Jonathan M. Loree, Van K. Morris, Robert Wolber
Publikováno v:
Clinical Cancer Research. 26:4599-4605
Purpose: BRAF V600E mutations portend poor prognosis in metastatic colorectal cancer (mCRC); however, the true prevalence and prognosis are unknown, as unwell patients may not undergo BRAF sequencing. Experimental Design: We reviewed a population-bas
Autor:
Meredith, Li, Faeze, Keshavarz-Rahaghi, Gale, Ladua, Lucas, Swanson, Caroline, Speers, Daniel J, Renouf, Howard J, Lim, Janine M, Davies, Sharlene, Gill, Heather C, Stuart, Stephen, Yip, Jonathan M, Loree
Publikováno v:
Therapeutic advances in medical oncology. 14
In metastatic colorectal cancer (mCRC),This retrospective review evaluated patients in British Columbia, Canada with mCRC andAge at diagnosis, sex, anatomic location and stage at diagnosis did not differ by
Autor:
Aly Karsan, François Rousseau, Guy A. Rouleau, André Caron, Lucas Swanson, Sylvie Langlois, Chad Fibke, Sylvie Giroux, Elizabeth Starks, Jeremy Parker, Loubna Jouan
Publikováno v:
Clinical chemistry and laboratory medicineReferences. 60(2)
Objectives Non-invasive prenatal testing requires the presence of fetal DNA in maternal plasma. Understanding how preexamination conditions affect the integrity of cell-free DNA (cfDNA) and fetal fraction (FF) are a prerequisite for test implementati
Autor:
Readman Chiu, Sergio Martinez-Høyer, Marco A. Marra, Richard A. Moore, Martin Jädersten, T. Roderick Docking, Andrew J. Mungall, Linda Chang, Gerben Duns, Aly Karsan, Karen Mungall, Donna E. Hogge, Ka Ming Nip, Ryan J. Stubbins, Lucas Swanson, Samantha Mar, Inanc Birol, Angela Mo, Jessica A. Pilsworth, Xuan Wang, Jihong Jiang, Simon K. Chan, Steven J.M. Jones, Jeremy Parker
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
Nature Communications
Nature Communications
As more clinically-relevant genomic features of myeloid malignancies are revealed, it has become clear that targeted clinical genetic testing is inadequate for risk stratification. Here, we develop and validate a clinical transcriptome-based assay fo
Autor:
Christina M. May, Sean S. Young, Tammy T.Y. Lau, Elizabeth Starks, Zahra J. Sefid Dashti, Anna V. Tinker, Tracy Tucker, Kasmintan A. Schrader, Lucas Swanson, Janice S. Kwon, Katie Compton, Aly Karsan, Jennifer F. De Los Santos, Sophie Sun, Ian Bosdet, Lien Hoang, Jeremy Parker, Richard A. Moore, Nili Heidary
Publikováno v:
The Journal of molecular diagnostics : JMD. 23(9)
Next-generation sequencing assays are capable of identifying cancer patients eligible for targeted therapies and can also detect germline variants associated with increased cancer susceptibility. However, these capabilities have yet to be routinely h
Autor:
Jenny E, Chu, Benny, Johnson, Laveniya, Kugathasan, Van K, Morris, Kanwal, Raghav, Lucas, Swanson, Howard J, Lim, Daniel J, Renouf, Sharlene, Gill, Robert, Wolber, Aly, Karsan, Scott, Kopetz, David F, Schaeffer, Jonathan M, Loree
Publikováno v:
Clin Cancer Res
PURPOSE: BRAF(V600E) mutations portend poor prognosis in metastatic colorectal cancer (mCRC); however, the true prevalence and prognosis are unknown, as unwell patients may not undergo BRAF sequencing. PATIENTS AND METHODS: We reviewed a population-b
Autor:
Meredith Li, Faeze Keshavarz-Rahaghi, Gale Ladua, Lucas Swanson, Caroline Speers, Daniel J. Renouf, Howard J. Lim, Janine M. Davies, Sharlene Gill, Heather C. Stuart, Stephen Yip, Jonathan M. Loree
Publikováno v:
Therapeutic Advances in Medical Oncology. 14:175883592210979
Introduction: In metastatic colorectal cancer (mCRC), RAS mutations impart inferior survival and resistance to anti-epidermal growth factor receptor (EGFR) antibodies. KRAS G12C inhibitors have been developed and we evaluated how KRAS G12C differs fr